Minoxidil
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Minoxidil: From Hypertension to Hypotrichosis Simplex of the Scalp
One-Sentence Summary
Minoxidil is a vasodilator, recorded in the knowledge graph for hypertensive disorders and alopecia. The TxGNN model predicts it may be effective for hypotrichosis simplex of the scalp, a rare hereditary hair loss disorder. Support is limited to 3 published case reports or case series and no registered clinical trials.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Hypertensive disorder, hypertension and alopecia (relations recorded in the knowledge graph; the Australian licence record contains no indication text) |
| Predicted New Indication | Hypotrichosis simplex of the scalp |
| TxGNN Prediction Score | 1.0000 |
| Evidence Level | L5 (the three cited studies are case reports that include the disease itself, but they do not support a higher level under this report’s rules; see below) |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Note on evidence level: The three publications do directly study hypotrichosis simplex of the scalp. However, all are single-patient or small case reports, mostly using minoxidil combined with other treatments (growth factors, botanical extracts, platelet-rich plasma). The data compiled for this report graded the evidence L4. Because the studies are case-level and confounded by co-treatment, I have taken the conservative view that they establish no more than a hypothesis. If the team accepts case reports as meeting the “directly studies the disease” threshold, the level would be L4.
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on general pharmacology, minoxidil is a potassium channel opener. Its active metabolite, minoxidil sulfate, is thought to prolong the anagen (growth) phase of the hair cycle and stimulate follicular proliferation and vascularisation.
Hereditary hypotrichosis simplex involves miniaturised or poorly sustained hair follicles. A drug that prolongs growth and supports follicles is therefore a plausible symptomatic treatment. The condition is caused by genetic variants (for example CDSN, APCDD1, RPL21), and minoxidil does not address these causes, so any benefit would likely be symptomatic rather than curative.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 35761391 | 2022 | Case report/series | Dermatologic Therapy | Hereditary hypotrichosis simplex of the scalp treated with oral minoxidil plus growth factors |
| 39902296 | 2024 | Case report | Frontiers in Genetics | Familial case in an 8-year-old boy with a CDSN mutation, treated with botanical extracts plus minoxidil |
| 36651821 | 2023 | Case report | Journal of Dermatological Treatment | 14-year-old patient treated with platelet-rich plasma injection plus topical minoxidil 2%; reported as successful |
All three are combination-therapy reports, so the contribution of minoxidil alone cannot be separated.
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 14041B | Loniten | Tablet 10 mg (oral) | Not stated in the data compiled for this report |
This is the only ARTG entry listed (single-ingredient, valid). It is an oral tablet; no topical formulation appears in the data.
Safety Considerations
Contraindication relations recorded in the knowledge graph (these are knowledge-graph relations, not label text) include:
- Cardiovascular: myocardial infarction, coronary thrombosis, heart disease, cardiovascular disease, pericarditis, pericardial effusion, haemopericardium, cardiac tamponade
- Cerebrovascular: stroke disorder, cerebrovascular disorder, cerebral infarction
- Blood pressure regulation: orthostatic hypotension, postural orthostatic tachycardia syndrome, multiple system atrophy
- Other: kidney disease, phaeochromocytoma and related adrenal or paraganglioma tumours, haemoglobinopathy, scalp dermatosis
Drug interactions (DDInter, 100 interactions in total; main ones shown):
- Moderate: corticosteroids (hydrocortisone, prednisolone, prednisone, dexamethasone, betamethasone, budesonide, triamcinolone), SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin, ertugliflozin), opioids (morphine, opium), cannabinoids (dronabinol, nabilone), bupropion, sapropterin
- Unknown severity: calcitriol, clotrimazole, metformin
Oral minoxidil at antihypertensive doses carries systemic cardiovascular risks. Please refer to the TGA-approved Product Information (PI) for label warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is very high, but the supporting evidence is three small combination-therapy case reports with no registered trials. Minoxidil does not address the genetic cause, and the only Australian licence is for a systemic oral tablet whose cardiovascular risks must be weighed against a cosmetic benefit in a rare, often paediatric, condition.
To proceed, the following is needed:
- Controlled or at least larger series data on minoxidil alone in hypotrichosis simplex
- Review of the Loniten PI for warnings and contraindications (currently a data gap)
- Mechanism of action data to support the mechanistic link
- A risk-benefit assessment of low-dose oral versus topical use, including paediatric safety
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.